Emergent BioSolutions and Substipharm Biologics Announce Strategic Manufacturing Partnership to Support Japanese Encephalitis Vaccine in the United States
Rhea-AI Summary
Emergent BioSolutions (NYSE: EBS) and Substipharm Biologics agreed to a ≈$34.5 million manufacturing services and distribution collaboration dated April 28, 2026. Emergent’s Canton, MA facility will manufacture IMOJEV® drug substance and serve as exclusive U.S. government distributor upon FDA approval.
The Canton site received an FDA "No Action Indicated" classification after a February 2026 inspection; Emergent has begun scale-up work and expects to hire additional staff later in 2026.
Positive
- Agreement valued at approximately $34.5 million
- Exclusive distributor to the U.S. government upon FDA approval
- Canton facility received FDA No Action Indicated after Feb 2026 inspection
- Emergent beginning scale-up and plans to hire additional employees in 2026
- Existing IMOJEV® inventory already maintained at Canton for Substipharm
Negative
- IMOJEV® is not approved for use in the U.S.
- Distribution to U.S. government contingent on future FDA regulatory approval
- Commercial scale-up depends on successful regulatory inspection readiness and scaling
News Market Reaction – EBS
On the day this news was published, EBS gained 2.49%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Partnership Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 09 | Supply partnership | Positive | -5.8% | NARCAN® supply deal for expanded BC Take Home Naloxone Program. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
The only prior partnership headline in the period saw a negative price reaction despite positive operational news.
Over recent months, Emergent BioSolutions has highlighted strategic moves, including a partnership to supply NARCAN® Nasal Spray for British Columbia’s expanded Take Home Naloxone Program on Apr 9, 2026. That partnership, backed by an $18 million CAD provincial investment, was followed by a -5.8% share move. Today’s manufacturing and distribution partnership around a Japanese Encephalitis vaccine extends this collaboration-focused strategy with a new product and geography dimension.
Key Terms
drug substance medical
bsl-2 medical
current good manufacturing practices regulatory
u.s. food & drug administration regulatory
regulatory submission regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Emergent’s Canton facility will manufacture drug substance and obtains exclusive distribution rights
GAITHERSBURG, Md. and GENEVA, April 28, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has entered into an agreement with Substipharm Biologics valued at approximately
Emergent Canton is a BSL-2, multi-product commercial facility that provides viral drug substance manufacturing. Following an inspection in February 2026, the FDA listed “No Action Indicated” status classification for the Canton manufacturing facility, reflecting Emergent’s commitment to ensuring continued compliance with current good manufacturing practices. Emergent has begun scale-up efforts at the Canton facility and intends to hire additional employees later this year.
Under a master Manufacturing Services Agreement, Emergent will conduct operational and regulatory inspection readiness activities and manufacture drug substance to support Substipharm’s U.S. regulatory submission for the vaccine with the FDA. The parties have entered into a distribution agreement under which Emergent will be the exclusive distributor of the vaccine to the U.S. government upon FDA approval. Emergent has previously manufactured IMOJEV® drug substance for international markets and continues to actively manage and maintain product inventory at the Canton facility for Substipharm.
Joe Papa, President and CEO of Emergent, commented: “This strategic manufacturing partnership is a critical step in our efforts to onshore production of critical medicines and leverage our specialized capabilities to support the U.S. government’s preparedness needs. In addition to supporting IMOJEV® drug substance manufacturing internationally, this partnership positions our Canton facility as a sustainable and flexible site that is well positioned for future strategic manufacturing partnerships.”
Fabrice Baschiera, CEO of Substipharm Biologics, stated: We’re pleased to partner with Emergent to accelerate our efforts to expand the global availability of our Japanese Encephalitis (JE) vaccine, IMOJEV®. This partnership allows us to leverage Emergent’s experience, specialized capabilities and track record in manufacturing complex biologics for the U.S. government, supporting regulatory approval and commercialization of the JE vaccine in the U.S. market and helping protect travelers to JE endemic regions.”
IMOJEV® is a JE vaccine that has been developed and used in several countries in Asia since 2012. Japanese Encephalitis is a mosquito-borne viral disease endemic in parts of Asia and the Western Pacific. It is not approved for use in the U.S.
About Emergent BioSolutions
At Emergent, our mission is to protect and save lives. For over 25 years, we’ve been at work preparing those entrusted with protecting public health. We deliver protective and life-saving solutions for health threats like smallpox, mpox, botulism, Ebola, anthrax and opioid overdose emergencies. To learn more about how we help prepare communities around the world for today’s health challenges and tomorrow’s threats, visit our website and follow us on LinkedIn, X, Instagram, Apple Podcasts and Spotify.
About Substipharm and Substipharm Biologics
Substipharm is a private French healthcare group headquartered in Paris, founded in 1995. The company develops, supplies and commercializes high-quality medicines and vaccines, operating in over 100 countries with a marketed portfolio of more than 90 molecules.
Substipharm Biologics is the group’s vaccines and biologics business, established following Substipharm’s 2022 acquisition of IMOJEV®, a Japanese Encephalitis vaccine, and its investment in a dedicated vaccine manufacturing facility in Bangkok, Thailand. Substipharm Biologics is based in Geneva, Switzerland, with a regional presence in Bangkok, and is focused on expanding access to vaccines and biologic medicines in Asia-Pacific and beyond.
Visit our website www.substipharm.com and follow us on LinkedIn.
Safe Harbor Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, are forward-looking statements. We generally identify forward-looking statements by using words like "anticipate," "believe," "continue," "could," "estimate," "expect," "forecast," "future," "goal," "intend," "may," "plan," "position," "possible," "potential," "predict," "project," "should," "target," "will," "would," and similar expressions or variations thereof, or the negative thereof, but these terms are not the exclusive means of identifying such statements. Forward-looking statements are based on our current intentions, beliefs and expectations regarding future events based on information that is currently available. We cannot guarantee that any forward-looking statement will be accurate. Readers should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from our expectations. Readers are, therefore, cautioned not to place undue reliance on any forward-looking statement. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, we do not undertake to update any forward-looking statement to reflect new information, events or circumstances.
There are a number of important factors that could cause the company's actual operational or financial results to differ materially from those indicated by any forward-looking statements. Readers should consider this cautionary statement, as well as the risk factors identified in our periodic reports filed with the U.S. Securities and Exchange Commission, when evaluating our forward-looking statements.
Emergent
Investor Contact:
Richard S. Lindahl
Executive Vice President, CFO
lindahlr@ebsi.com
Media Contact:
Assal Hellmer
Vice President, Communications
mediarelations@ebsi.com
Substipharm
Media contact:
Raphaëlle Tisserand-Quéré
rtisserand@substipharm.com
